Press Releases

 
Press Releases
  Date Title and Summary View
Jun 30, 2016
75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations BURLINGTON, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that preliminary data presented at ESMO GI demonstrate evidence of anticancer activity, defined by objecti...
Jun 23, 2016
BURLINGTON, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in intrahepatic cholangiocarcinoma (iCCA) with our proprietary fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, will be presented on June 30, 2016 at the ESMO 18th ...
May 4, 2016
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the first quarter of 2016.  For the quarter ended March 31, 2016, the Company reported a net loss of $4,981,000 or $0.08 per share, compared with a net loss of $4,551,000 or...
Apr 20, 2016
BURLINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the first quarter 2016 before the market opens on Wednesday, May 4, 2016.  The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business...
Apr 5, 2016
BURLINGTON, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 15th Annual Needham Healthcare Conference on April 12th, 2016, at 2:20 p.m. ET at the Westin Grand Centr...
Mar 22, 2016
Independent Data Monitoring Committee (DMC) Conducts Interim Assessment BURLINGTON, Mass. and PARSIPPANY, N.J., March 22, 2016 (GLOBE NEW...
Feb 29, 2016
Conference Call Scheduled Today at 9:00 a.m. ET BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the fourth quarter and full year of 2015.  For the quarter ended December 31, 2015, the Company reported a net loss of $2,852,000 or $0.05 per share, compared with net los...
Feb 29, 2016
BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it has entered into definitive agreements with certain institutional and accredited investors to raise approximately $15.3 million in gross proceeds in a registered direct offering through the sale of 8,027,900 shares of common stock at an offering pri...
Feb 15, 2016
BURLINGTON, Mass., Feb. 15, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it will report financial results for the fourth quarter and full year 2015 before the market opens on Monday, February 29, 2016.  The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a...
Feb 4, 2016
BURLINGTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the following conferences: Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300